GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ORGO · Jun 30, 2026

Organogenesis Holdings Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-338049General Corporate

Capex intensity60thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.51% · OPTIONAL · VALID

Operating cash generation0thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-72.34% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-56.68% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure90thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

66.92% · OPTIONAL · VALID

Operating margin10thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.operating_margin

-116.54% · CORE · VALID

R&D intensity100thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

41.82% · OPTIONAL · VALID

SBC intensity90thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

6.98% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/8 normalizedLevel 3 Jun 30, 20240/8 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20256/7 normalizedLevel 3 Mar 31, 20266/7 normalizedLevel 3 Jun 30, 20266/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 8.45%
Current: 2.51%
Delta: -5.94%

Cash Generation Decreased

Previous: 56.75%
Current: -72.34%
Delta: -129.09%

Growth Increased

Previous: -57.06%
Current: -56.68%
Delta: 0.38%

Inventory Pressure Decreased

Previous: 76.35%
Current: 66.92%
Delta: -9.44%

Profitability Increased

Previous: -185.05%
Current: -116.54%
Delta: 68.51%

R And D Intensity Increased

Previous: 40.72%
Current: 41.82%
Delta: 1.09%

Sbc Intensity Decreased

Previous: 9.77%
Current: 6.98%
Delta: -2.79%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Transitioned To · ORGO Fundamental State →Transitioned To · ORGO CAPEX_INTENSITY_DECREASED →Transitioned To · ORGO CASH_GENERATION_DECREASED →Transitioned To · ORGO GROWTH_INCREASED →Transitioned To · ORGO INVENTORY_PRESSURE_DECREASED →Transitioned To · ORGO PROFITABILITY_INCREASED →Transitioned To · ORGO R_AND_D_INTENSITY_INCREASED →Transitioned To · ORGO SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.